Journal of Oncology

Research Article

GJA1 rs2071165 A > G Variant Increased Gastric Cancer Risk in Females of Northwest China: A Case-Control Study

Table 4

Stratification analyses for the association between GJA1 rs2071165 G> A polymorphism and gastric cancer susceptibility in females.


	Model	Genotype	Case	Control	OR (95% CI)		OR (95% CI)	¹

Age
≥55	Codominant	GG	38	105	1.00	0.26	1.00	0.25
		AG	33	66	1.38 (0.79–2.42)		1.42 (0.78–2.56)
		AA	6	9	1.84 (0.61–5.52)		2.15 (0.67–6.88)
	Dominant	GG	38	105	1.00	0.19	1.00	0.16
	Dominant	AA/AG	39	75	1.44 (0.84–2.46)	0.19	1.50 (0.85–2.64)	0.16
	Recessive	AG/GG	71	171	1.00	0.39	1.00	0.28
	Recessive	AA	6	9	1.61 (0.55–4.68)	0.39	1.86 (0.60–5.75)	0.28

<55	Codominant	GG	39	56	1.00	0.11	1.00	0.10
		AG	33	28	1.69 (0.88–3.24)		1.85 (0.88–3.88)
		AA	5	3	2.39 (0.54–10.60)		4.52 (0.93–22.00)
	Dominant	GG	39	56	1.00	0.08	1.00	0.046
	Dominant	AA/AG	38	31	1.76 (0.94–3.93)	0.08	2.06 (1.01–4.21)	0.046
	Recessive	AG/GG	72	84	1.00	0.37	1.00	0.11
	Recessive	AA	5	3	1.94 (0.45–8.42)	0.37	3.51 (0.75–16.53)	0.11

Tumor size^a
≥5 cm	Codominant	GG	32	161	1.00	0.07	1.00	0.08
		AG	31	94	1.66 (0.95–2.89)		1.66 (0.95–2.89)
		AA	6	12	2.52 (0.88–7.20)		2.53 (0.88–7.23)
	Dominant	GG	32	161	1.00	0.04	1.00	0.04
	Dominant	AA/AG	37	106	1.76 (1.03–2.99)	0.04	1.753 (1.03–2.99)	0.04
	Recessive	AG/GG	63	255	1.00	0.17	1.00	0.17
	Recessive	AA	6	12	2.02 (0.73–5.60)	0.17	2.04 (0.73–5.64)	0.17

<5 cm	Codominant	GG	41	161	1.00	0.17	1.00	0.21
		AG	34	94	1.42 (0.84–2.39)		1.42 (0.82–2.46)
		AA	5	12	1.64 (0.55–4.91)		2.01 (0.64–6.34)
	Dominant	GG	41	161	1.00	0.15	1.00	0.15
	Dominant	AA/AG	39	106	1.45 (0.87–2.39)	0.15	1.48 (0.87–2.51)	0.15
	Recessive	AG/GG	75	255	1.00	0.52	1.00	0.33
	Recessive	AA	5	12	1.42 (0.48–4.15)	0.52	1.75 (0.57–5.36)	0.33

Clinical stage^a
0/I/II	Codominant	GG	56	161	1.00	0.26	1.00	0.19
		AG	43	94	1.32 (0.82–2.11)		1.38 (0.85–2.23)
		AA	5	12	1.20 (0.40–3.55)		1.28 (0.42–3.85)
	Dominant	GG	56	161	1.00	0.26	1.00	0.17
	Dominant	AA/AG	48	106	1.30 (0.82–2.06)	0.26	1.37 (0.86–2.18)	0.17
	Recessive	AG/GG	99	255	1.00	0.90	1.00	0.84
	Recessive	AA	5	12	1.07 (0.37–3.13)	0.90	1.12 (0.38–3.32)	0.84

III/IV	Codominant	GG	20	161	1.00	0.01	1.00	0.01
		AG	22	94	1.88 (0.98–3.63)		1.83 (0.94–3.54)
		AA	6	12	4.03 (1.36–11.91)		4.19 (1.41–12.45)
	Dominant	GG	20	161	1.00	0.02	1.00	0.02
	Dominant	AA/AG	28	106	2.13 (1.14–3.97)	0.02	2.09 (1.12–3.91)	0.02
	Recessive	AG/GG	42	255	1.00	0.04	1.00	0.03
	Recessive	AA	6	12	3.036 (1.08–8.53)	0.04	3.21 (1.14–9.08)	0.03

Recurrence/metastasis^a
Negative	Codominant	GG	35	161	1.00	0.04	1.00	0.03
		AG	36	94	1.76 (1.04–2.99)		1.82 (1.06–3.10)
		AA	7	12	2.68 (0.99–7.30)		2.84 (1.03–7.80)
	Dominant	GG	35	161	1.00	0.02	1.00	0.01
	Dominant	AA/AG	43	106	1.87 (1.12–3.105)	0.02	1.93 (1.16–3.23)	0.01
	Recessive	AG/GG	71	255	1.00	0.13	1.00	0.12
	Recessive	AA	7	12	2.095 (0.795–5.52)	0.13	2.18 (0.82–5.80)	0.12

Positive	Codominant	GG	41	161	1.00	0.49	1.00	0.58
		AG	29	94	1.21 (0.71–2.08)		1.17 (0.68–2.03)
		AA	4	12	1.31 (0.40–4.27)		1.41 (0.43–4.63)
	Dominant	GG	41	161	1.00	0.45	1.00	0.51
	Dominant	AA/AG	33	106	1.22 (0.3–2.06)	0.45	1.20 (0.70–2.03)	0.51
	Recessive	AG/GG	70	255	1.00	0.74	1.00	0.64
	Recessive	AA	4	12	1.21 (0.38–3.88)	0.74	1.32 (0.41–4.27)	0.64

¹Adjusted by age. Stage 0 was added to the clinical stage I/II. ^aPatient numbers may not add up to 100% of available subjects because of missing clinical data.